Armata Pharma Q4 net loss $124.3M on $105.8M non-cash fair value loss; going concern noted

Armata Pharmaceuticals, Inc.

Q4 2025 grant revenue $1.1M vs $1.2M YoY; R&D expenses $6.1M vs $8.5M YoY.
Net loss $124.3M ($3.42/sh) vs net income $2.6M ($0.07/sh) in Q4 2024; includes $105.8M non-cash fair value loss on convertible loan.
Recognized $5.4M impairment expense on vacated Marina del Rey office lease.
Cash & equivalents $14.1M as of Dec 31 2025; amended debt agreements extending maturities to June 2027.
Audited 2025 financials include going concern qualification; ~36.6M shares outstanding as of Mar 18 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Armata Pharmaceuticals, Inc. reported the three months and full fiscal year ended December 31, 2025 results: net income $124.3 million, EPS $(3.42) per share.

Period: the three months and full fiscal year ended December 31, 2025
Net income: $124.3 million
EPS: $(3.42) per share
Result: reported results

Exact text from the filing

Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, in the press release furnished hereto as Exhibit 99.1.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-034523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.